Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 7/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13874085 | 0.89 | CCR3 (0.51) | MEN1KMT2ASMN1; SMN2CCR3GLA | |
| SCHEMBL13873636 | 0.81 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2CCR3GLA | |
| SCHEMBL13873799 | 0.80 | CHRNA7 (0.52) | MEN1KMT2ASMN1; SMN2CCR3GLA | |
| SCHEMBL13873808 | 0.79 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2CCR3GLA | |
| SCHEMBL13873627 | 0.79 | EPHX2 (0.61) | MEN1KMT2ASMN1; SMN2CCR3GLA | |
| SCHEMBL13873630 | 0.77 | SMN1; SMN2 (0.63) | MEN1KMT2ASMN1; SMN2MMP1MMP3 | |
| SCHEMBL13873626 | 0.77 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2CCR3GLA | |
| SCHEMBL24449599 | 0.77 | GLA (0.53) | MEN1KMT2ASMN1; SMN2GLACHRNA7 | |
| SCHEMBL13873798 | 0.77 | SMN1; SMN2 (0.57) | MEN1KMT2ASMN1; SMN2NPC1MMP1 | |
| SCHEMBL13874097 | 0.76 | EPHX2 (0.55) | SMN1; SMN2CCR3PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | MEN1 4174/4885KMT2A 3145/4885SMN1; SMN2 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.